Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific

摘要

According to World Health Organization (WHO) estimates,. 33.4 million people were infected with the human immunodeficiency virus (HIV) type 1 globally at the end of 2008.] Sub-Saharan Africa and Asia are the two regions that have the highest HIV prevalence, with 22.4 and 4.7 million people infected, respectively. During the 5 years prior, access to combination antiretroviral therapy (ART) in low- and middle-income countries increased 10-fold to reach 4 million people, providing coverage to 28% of those in need. Several studies have reported significant reductions in HIV-related morbidity and mortality for individuals with access to treatment in these regions.